ZLJ-6

• CAT Number: I011558
• CAS Number: 1051931-39-5
• Molecular Formula: C12H13N3O3S • CH3SO3H
• Molecular Weight: 375.41
• Purity: ≥95%
• Synonyms: (5Z)-2-amino-1,5-dihydro-1-methyl-5-[[4-(methylsulfonyl)phenyl]methylene]-4H-imidazol-4-one, monomethanesulfonate
• Target: Metabolic Enzyme/Protease
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• IUPAC Name: (5Z)-2-imino-1-methyl-5-[(4-methylsulfonylphenyl)methylidene]imidazolidin-4-one;methanesulfonic acid
• InChI: InChI=1S/C12H13N3O3S.CH4O3S/c1-15-10(11(16)14-12(15)13)7-8-3-5-9(6-4-8)19(2,17)18;1-5(2,3)4/h3-7H,1-2H3,(H2,13,14,16);1H3,(H,2,3,4)/b10-7-
• InChIKey: QEJPXTVPNIOEHZ-VEZAGKLZSA-N
• SMILES: CN1/C(=C\C2=CC=C(C=C2)S(=O)(=O)C)/C(=O)NC1=N.CS(=O)(=O)O

ZLJ-6(CAT: I011558) is a potent and selective inhibitor of human ATP-citrate lyase (ACLY), a key enzyme in lipid biosynthesis and metabolic regulation. By targeting ACLY, ZLJ-6 disrupts the conversion of citrate to acetyl-CoA, effectively reducing lipid synthesis and modulating metabolic pathways. It is widely used in research focused on cancer metabolism, obesity, and other metabolic disorders where ACLY plays a critical role. ZLJ-6 is a valuable tool for studying lipid metabolism, exploring therapeutic strategies, and advancing drug development targeting ACLY-related pathways. Its high specificity and efficacy make it ideal for preclinical and biochemical studies.